M&A analysis: bolt-ons for J&J and Bristol
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
Innovent gives another cytokine a shot
Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.
Black Diamond advances in brain cancer
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
ArriVent moves to take on Rybrevant
Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
J&J’s new trispecific play
JNJ-95566692 enters phase 1, with Qilu neck and neck.
A new clinical KRAS degrader
Three private biotechs enter clinical trials, one targeting KRAS.
Rakuten sheds light on its conjugate
The company secures funding to push its lead candidate towards US approval.
Incyte does TGF-beta differently
Four months after yielding first-in-human data INCA33890 enters phase 3.
The month ahead: January’s remaining events
JP Morgan approaches.
